IL163586A0 - Methods of preventing or treating brain ischemia or brain injury - Google Patents
Methods of preventing or treating brain ischemia or brain injuryInfo
- Publication number
- IL163586A0 IL163586A0 IL16358603A IL16358603A IL163586A0 IL 163586 A0 IL163586 A0 IL 163586A0 IL 16358603 A IL16358603 A IL 16358603A IL 16358603 A IL16358603 A IL 16358603A IL 163586 A0 IL163586 A0 IL 163586A0
- Authority
- IL
- Israel
- Prior art keywords
- brain
- preventing
- methods
- treating
- ischemia
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35906102P | 2002-02-21 | 2002-02-21 | |
| PCT/US2003/005090 WO2003072543A2 (en) | 2002-02-21 | 2003-02-20 | Methods of preventing or treating brain ischemia or brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL163586A0 true IL163586A0 (en) | 2005-12-18 |
Family
ID=27766036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16358603A IL163586A0 (en) | 2002-02-21 | 2003-02-20 | Methods of preventing or treating brain ischemia or brain injury |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7202211B2 (enExample) |
| EP (1) | EP1476179A2 (enExample) |
| JP (1) | JP2005518443A (enExample) |
| AU (1) | AU2003223184A1 (enExample) |
| CA (1) | CA2476765A1 (enExample) |
| IL (1) | IL163586A0 (enExample) |
| WO (1) | WO2003072543A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223184A1 (en) * | 2002-02-21 | 2003-09-09 | Fujisawa Pharmaceutical Co., Ltd. | Methods of preventing or treating brain ischemia or brain injury |
| CN1605336A (zh) * | 2003-10-10 | 2005-04-13 | 中国医学科学院药物研究所 | 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用 |
| RU2293513C2 (ru) * | 2004-11-12 | 2007-02-20 | Главное военно-медицинское управление Министерства обороны Российской Федерации | Способ экспресс-диагностики обратимости ишемического повреждения мягких тканей и устройство для его осуществления |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| WO2014135694A1 (en) | 2013-03-08 | 2014-09-12 | Csl Behring Ag | Treatment and prevention of remote ischemia-reperfusion injury |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341762A (en) | 1981-04-07 | 1982-07-27 | Haast William E | Use of snake venoms for treatment of neurological and related disorders |
| US6316602B1 (en) | 1994-05-03 | 2001-11-13 | Binie V. Lipps | Beta taipoxin as a cell growth factor and method |
| US5767252A (en) | 1996-04-08 | 1998-06-16 | The Johns Hopkins University School Of Medicine | Neuronal cell growth factor, Narp |
| US6124610A (en) * | 1998-06-26 | 2000-09-26 | Advanced Micro Devices, Inc. | Isotropically etching sidewall spacers to be used for both an NMOS source/drain implant and a PMOS LDD implant |
| WO2000075661A1 (en) | 1999-06-09 | 2000-12-14 | The Johns Hopkins University School Of Medicine | Method for identifying compounds which affect synaptogenesis |
| EP1101820A1 (en) | 1999-11-15 | 2001-05-23 | MERCK PATENT GmbH | Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| AU2001233954A1 (en) | 2000-02-24 | 2001-09-03 | Oxford Glycosciences (Uk) Ltd. | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| AU2003223184A1 (en) * | 2002-02-21 | 2003-09-09 | Fujisawa Pharmaceutical Co., Ltd. | Methods of preventing or treating brain ischemia or brain injury |
-
2003
- 2003-02-20 AU AU2003223184A patent/AU2003223184A1/en not_active Abandoned
- 2003-02-20 WO PCT/US2003/005090 patent/WO2003072543A2/en not_active Ceased
- 2003-02-20 IL IL16358603A patent/IL163586A0/xx unknown
- 2003-02-20 JP JP2003571249A patent/JP2005518443A/ja active Pending
- 2003-02-20 EP EP03719313A patent/EP1476179A2/en not_active Withdrawn
- 2003-02-20 CA CA002476765A patent/CA2476765A1/en not_active Abandoned
- 2003-02-20 US US10/371,725 patent/US7202211B2/en not_active Expired - Lifetime
-
2007
- 2007-02-12 US US11/705,644 patent/US20070173453A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003072543A2 (en) | 2003-09-04 |
| US20030219430A1 (en) | 2003-11-27 |
| CA2476765A1 (en) | 2003-09-04 |
| AU2003223184A8 (en) | 2003-09-09 |
| EP1476179A2 (en) | 2004-11-17 |
| US7202211B2 (en) | 2007-04-10 |
| JP2005518443A (ja) | 2005-06-23 |
| WO2003072543A3 (en) | 2004-05-21 |
| AU2003223184A1 (en) | 2003-09-09 |
| US20070173453A1 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
| EP1617805A4 (en) | METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS | |
| AU2003295537A8 (en) | Methods of treating cerebral ischemia | |
| IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
| HUS2200036I1 (hu) | Dihidroimidazolonok alkalmazása kutyák kezelésére | |
| EP1677794A4 (en) | METHODS OF TREATING DISORDERS | |
| EP1505961A4 (en) | METHOD FOR TREATING ALLERGIC REACTIONS | |
| PL368556A1 (en) | Methods for treating or preventing skin disorders using cd2-binding agents | |
| AU2003249181A8 (en) | Methods for treating or preventing ischemic injury | |
| GB0213869D0 (en) | The treatment of pain | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| AU2003223184A8 (en) | Methods of preventing or treating brain ischemia or brain injury | |
| EP1539100A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS | |
| GB0217493D0 (en) | Novel methods of treatment | |
| EP1560592A4 (en) | TREATMENT OF ALLGIELES | |
| IL161630A0 (en) | Methods of treating endometreosis | |
| PL1867644T3 (pl) | Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu | |
| GB0221712D0 (en) | Methods of treatment | |
| AUPS165902A0 (en) | Methods of treating brca associated disorder | |
| ZA200604723B (en) | Agents for preventing and/or treating higher brain dysfunctions | |
| GB0213198D0 (en) | Method of treatment | |
| GB0210210D0 (en) | Treatment of hydrocarbons | |
| AU2003213963A8 (en) | Method of treating or preventing autoimmune disease | |
| GB0111070D0 (en) | Treatment of cerebral ischemia | |
| SI1487829T1 (sl) | Tiadiazolilpiperazinski derivati, uporabni za zdravljenje ali preprecevanje bolecine |